Ranibizumab treatment administered as needed for occult and minimally classic neovascular membranes in age-related macular degeneration
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
To report the clinical experience of intravitreal ranibizumab administered as needed for the treatment of neovascular age-related macular degeneration (AMD).
We retrospectively reviewed the charts of 41 patients (41 eyes) with occult and minimally classic neovascular membrane in AMD. Patients received intravitreal injections (0.5 mg) of ranibizumab and were monitored monthly for 12 months. Forty-one eyes were retreated at the discretion of the treating physician on an as-needed basis after the first injection, instead of initially giving three monthly injections. The main outcomes measured were change in mean visual acuity and central retinal thickness, and the total number of injections received by patients during the 12 months.
At 12 months, the mean logarithm of the minimum angle of resolution (logMAR) visual acuity improved by 0.078 logMAR units (P = 0.046) and the mean central retinal thickness decreased by 85.7 μm (P < 0.001). Thirty of 41 eyes (73.2%) avoided any loss of vision, and 20 eyes (48.8 %) showed improved visual acuity. A mean of 4.07 injections were given over the 12 months.
Ranibizumab administered on an as-needed basis may stabilize visual acuity in patients with neovascular AMD.
- Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–1431. CrossRef
- Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432–1444. CrossRef
- Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration. A phase I/II multicenter, controlled, multidose study. Ophthalmology 2006; 113:633–642. CrossRef
- Regillo CD, Brown DM, Abraham P, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular agerelated macular degeneration; PIER study year 1. Am J Ophthalmol 2008;145:239–248. CrossRef
- Fung AE, Laiwani GA, Resenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566–583. CrossRef
- Mantel I, Zografos L, Ambresin A. Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration. Ophthalmologica 2008;222:321–323. CrossRef
- Heier JS, Boyer DS, Gulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124:1932–1942. CrossRef
- Coleman HR, Chan CC, Ferris FL 3rd, Chew EY. Age-related macular degeneration. Lancet 2008;372:1835–1845. CrossRef
- Kourlas H, Abrams P. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther 2007;29:1850–1861. CrossRef
- Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J. Ranibizumab for neovascular age-related macular degeneration. Am J Health Syst Pharm 2008;65:1805–1814. CrossRef
- Falkenstein IA, Cochran DE, Azen SP, et al. Comparison of visual acuity in macular degeneration patients measured with Snellen and early treatment diabetic retinopathy study charts. Ophthalmology 2008;115:319–323. CrossRef
- Sloan LL. New test charts for the measurement of visual acuity at far and near distances. Am J Ophthalmol 1959;48:807–813.
- Fong KC, Kirkpatrick N, Mohamed Q, Johnston RL. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment. Clin Experiment Ophthalmol 2008;36:748–755. CrossRef
- Arias L, Caminal JM, Casas L, et al. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol 2008;92:1636–1641. CrossRef
- Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1–9. CrossRef
- Giansanti F, Virgili G, Bini A, et al. Intravitreal bevacizumab therapy for choroidal neovascularization secondary to age-related macular degeneration: 6-month results of an open-label uncontrolled clinical study. Eur J Ophthalmol 2007;17:230–237.
- Ranibizumab treatment administered as needed for occult and minimally classic neovascular membranes in age-related macular degeneration
Japanese Journal of Ophthalmology
Volume 55, Issue 2 , pp 123-127
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- age-related macular degeneration
- as-needed basis
- intravitreal injection
- Industry Sectors
- Author Affiliations
- 1. Department of Ophthalmology and Visual Science, St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 2. Department of Ophthalmology and Visual Science, St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 62 Yoido-dong, Youngdungpo-gu, Seoul, 150-713, Korea